Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Introduction Cigarette smoking is a leading cause of death and morbidity worldwide
Tirzepatides cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of 2026, so this comparison may change once those results are published
Lets be direct
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
US$ 29.06
US$ 22.53
US$ 29.34
US$ 25.26
US$ 24.55
US$ 22.29
US$ 24.74
US$ 22.96
US$ 21.49
US$ 22.44
US$ 29.15
